Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how advancing drug pipelines are increasingly being recognized as measurable financial assets under U.S. GAAP, reflecting a broader shift in biotech valuation. The company was noted for leveraging its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio, recently valued at more than $1 billion, as an example of how scientific progress and proximity to commercialization can directly enhance balance sheet value and investor perception.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer